NO20052019L - Blanding for a inhibere sekresjon av magesyre - Google Patents
Blanding for a inhibere sekresjon av magesyreInfo
- Publication number
- NO20052019L NO20052019L NO20052019A NO20052019A NO20052019L NO 20052019 L NO20052019 L NO 20052019L NO 20052019 A NO20052019 A NO 20052019A NO 20052019 A NO20052019 A NO 20052019A NO 20052019 L NO20052019 L NO 20052019L
- Authority
- NO
- Norway
- Prior art keywords
- dosage form
- gastric acid
- mixture
- receptor antagonist
- acid secretion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
2005-06-15 Sammendrag: Oral farmasøytisk doseringsform som omfatter farmakologisk effektive mengder av en syrefølsom protonpumpe-inhibitor og en H2-reseptor-antagonist i kombinasjon med minst ett farmakologisk akseptabelt hjelpestoff som forårsaker forsinket frigjøring og/eller en forlenget frigjøring av protonpumpe-inhibitoren. H2-reseptor antagonisten er innlemmet i doseringsformen på en slik måte at den raskt frigjøres etter administrering. Denne doseringsformen er egnet i behandling av tilstander forbundet med en overdreven utskilling av magesyre og etablerer en egnet kombinasjon av en rask igangsetting og lang varighet av effekten. Oppfinnelsen angår også en framgangsmåte for framstilling av en slik doseringsform og en framgangsmåte for behandling av tilstander forbundet med utskillingen av magesyre. Fig. 1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0203065A SE0203065D0 (sv) | 2002-10-16 | 2002-10-16 | Gastric acid secretion inhibiting composition |
PCT/SE2003/001598 WO2004035090A1 (en) | 2002-10-16 | 2003-10-15 | Gastric acid secretion inhibiting composition |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20052019D0 NO20052019D0 (no) | 2005-04-26 |
NO20052019L true NO20052019L (no) | 2005-06-15 |
Family
ID=20289290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20052019A NO20052019L (no) | 2002-10-16 | 2005-04-26 | Blanding for a inhibere sekresjon av magesyre |
Country Status (14)
Country | Link |
---|---|
US (5) | US7785626B2 (no) |
EP (2) | EP2258341A3 (no) |
JP (2) | JP2006505566A (no) |
KR (1) | KR101139862B1 (no) |
CN (1) | CN1726048B (no) |
AU (1) | AU2003267924C1 (no) |
CA (1) | CA2501201C (no) |
MX (1) | MXPA05004118A (no) |
NO (1) | NO20052019L (no) |
NZ (1) | NZ539262A (no) |
PL (1) | PL376178A1 (no) |
RU (1) | RU2340358C2 (no) |
SE (1) | SE0203065D0 (no) |
WO (1) | WO2004035090A1 (no) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
WO2003084518A2 (fr) | 2002-04-09 | 2003-10-16 | Flamel Technologies | Suspension orale de microcapsules de principes actifs |
AR045068A1 (es) * | 2003-07-23 | 2005-10-12 | Univ Missouri | Formulacion de liberacion inmediata de composiciones farmaceuticas |
US20060046998A1 (en) * | 2004-08-25 | 2006-03-02 | Fairfield Clinical Trials, Llc | Method of treatment of gastroesophageal reflux disease and laryngopharyngeal reflux disease |
US20060165797A1 (en) * | 2005-01-12 | 2006-07-27 | Pozen Inc. | Dosage form for treating gastrointestinal disorders |
WO2006099618A1 (en) * | 2005-03-16 | 2006-09-21 | Dr. Reddy's Laboratories Ltd. | Delivery system for multiple drugs |
US20070015782A1 (en) | 2005-04-15 | 2007-01-18 | Eisai Co., Ltd. | Benzimidazole compound |
WO2006118017A1 (ja) * | 2005-04-28 | 2006-11-09 | Eisai R & D Management Co., Ltd. | 安定化組成物 |
US9040564B2 (en) | 2005-04-28 | 2015-05-26 | Eisai R&D Management Co., Ltd. | Stabilized composition |
WO2006122835A1 (en) | 2005-05-18 | 2006-11-23 | Da Volterra | Colonic delivery of adsorbents |
UA94916C2 (ru) * | 2005-09-09 | 2011-06-25 | Лабофарм Инк. | Композиция тразодона для введения один раз в день |
US20070160960A1 (en) * | 2005-10-21 | 2007-07-12 | Laser Shot, Inc. | System and method for calculating a projectile impact coordinates |
CA2634637A1 (en) * | 2005-12-28 | 2007-07-05 | Takeda Pharmaceutical Company Limited | Controlled release solid preparation |
KR20080081071A (ko) * | 2005-12-28 | 2008-09-05 | 다케다 야쿠힌 고교 가부시키가이샤 | 방출 제어 고형 제제 |
US8048413B2 (en) | 2006-05-17 | 2011-11-01 | Helene Huguet | Site-specific intestinal delivery of adsorbents, alone or in combination with degrading molecules |
JP5233108B2 (ja) * | 2006-10-24 | 2013-07-10 | ゼリア新薬工業株式会社 | ニザチジン含有医薬組成物 |
CA2740974A1 (en) * | 2008-05-30 | 2009-12-03 | Pozen Inc. | Dosage forms for the rapid and sustained elevation of gastric ph |
WO2010017821A1 (en) * | 2008-08-14 | 2010-02-18 | Daniel Bar-Shalom | Coated tablets with a remaining degradation surface over the time8 |
MX2011002515A (es) | 2008-09-09 | 2011-04-07 | Astrazeneca Ab | Metodo de administracion de una composicion farmaceutica a un paciente que lo necesita. |
WO2010038241A2 (en) * | 2008-09-30 | 2010-04-08 | Panacea Biotec Limited | Pharmaceutical compositions comprising of proton pump inhibitor, prokinetic agent and alginic acid |
WO2010096820A1 (en) * | 2009-02-23 | 2010-08-26 | Eurand, Inc. | Controlled release compositions comprising anti-cholinergic drugs |
MX2011013467A (es) | 2009-06-25 | 2012-02-13 | Astrazeneca Ab | Metodo para tratar un paciente que corre el riesgo de desarollar una ulcera asociada a antiinflamatorio no esteroide (aine). |
BR112012005163A2 (pt) * | 2009-09-08 | 2016-05-03 | Kyowa Chem Ind Co Ltd | comprimido antiácido e laxante compreendendo partículas de óxido de magnésio, processo para produzir um comprimido antiácido e laxante, e, uso do comprimido |
WO2011080501A2 (en) | 2009-12-29 | 2011-07-07 | Orexo Ab | New pharmaceutical dosage form for the treatment of gastric acid-related disorders |
WO2011080500A2 (en) | 2009-12-29 | 2011-07-07 | Orexo Ab | New pharmaceutical dosage form for the treatment of gastric acid-related disorders |
WO2011080502A2 (en) | 2009-12-29 | 2011-07-07 | Orexo Ab | New pharmaceutical dosage form for the treatment of gastric acid-related disorders |
CN101912363A (zh) * | 2010-07-29 | 2010-12-15 | 蔡海德 | 溶解超滤-喷雾干燥-分子分散包衣-水化制粒-冷冻干燥生产脂质体组合药物 |
BR112014016085A8 (pt) | 2011-12-28 | 2017-07-04 | Pozen Inc | composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico |
KR101639692B1 (ko) * | 2013-12-13 | 2016-07-14 | 제일약품주식회사 | 2 이상의 유효성분을 포함하는 구강 내 속붕해 다중유닛 약제학적 조성물 |
EP3288556A4 (en) | 2015-04-29 | 2018-09-19 | Dexcel Pharma Technologies Ltd. | Orally disintegrating compositions |
MA46597A (fr) * | 2015-05-29 | 2019-09-04 | Johnson & Johnson Consumer Inc | Utilisation d'extrait d'agrumes biologiques à capacité antimicrobienne élevée en tant que système de conservation dans des liquides, des émulsions, des suspensions, des crèmes et des anti-acides |
CN105796532B (zh) * | 2016-03-28 | 2018-12-21 | 中国医药集团总公司四川抗菌素工业研究所 | 一种雷贝拉唑钠缓释胶囊及其制备方法 |
US10076494B2 (en) | 2016-06-16 | 2018-09-18 | Dexcel Pharma Technologies Ltd. | Stable orally disintegrating pharmaceutical compositions |
CN105944104B (zh) * | 2016-06-17 | 2018-12-14 | 上海凯宝药业股份有限公司 | 一种治疗消化道溃疡的药物组合物 |
WO2018183881A1 (en) * | 2017-03-31 | 2018-10-04 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceuticals ingredients |
KR102080023B1 (ko) | 2018-01-29 | 2020-02-21 | 주식회사 종근당 | 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물 |
KR102006777B1 (ko) * | 2018-01-29 | 2019-10-08 | 주식회사 종근당 | 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제 |
AU2019259791B2 (en) | 2018-04-27 | 2024-03-28 | Johnson & Johnson Consumer Inc. | Liquid oral pharmaceutical dosage form |
WO2024042540A1 (en) * | 2022-08-24 | 2024-02-29 | Alkem Laboratories Limited | Mesdopetam compositions |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE7804231L (sv) | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
JPS6056143B2 (ja) | 1979-08-02 | 1985-12-09 | 山之内製薬株式会社 | アミジン誘導体ならびにその製造法 |
DE3400014A1 (de) | 1984-01-02 | 1985-07-18 | Henkel KGaA, 4000 Düsseldorf | Entschaeumer fuer waessrige dispersionen und loesungen von kunstharzen |
IL75400A (en) | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
JPS6150978A (ja) | 1984-08-16 | 1986-03-13 | Takeda Chem Ind Ltd | ピリジン誘導体およびその製造法 |
AU4640985A (en) | 1984-08-31 | 1986-03-06 | Nippon Chemiphar Co. Ltd. | Benzimidazole derivatives |
GB8809421D0 (en) | 1988-04-21 | 1988-05-25 | Fordonal Sa | Antacid compositions with prolonged gastric residence time |
SE8804629D0 (sv) | 1988-12-22 | 1988-12-22 | Ab Haessle | New therapeutically active compounds |
US5204118A (en) * | 1989-11-02 | 1993-04-20 | Mcneil-Ppc, Inc. | Pharmaceutical compositions and methods for treating the symptoms of overindulgence |
SE9002206D0 (sv) | 1990-06-20 | 1990-06-20 | Haessle Ab | New compounds |
ATE184602T1 (de) | 1990-06-20 | 1999-10-15 | Astra Ab | Dialkoxypyridinylbenzimidazolderivate, verfahren zur herstellung und ihre pharmazeutische verwendung |
US5244670A (en) * | 1991-04-04 | 1993-09-14 | The Procter & Gamble Company | Ingestible pharmaceutical compositions for treating upper gastrointestinal tract distress |
US5225202A (en) | 1991-09-30 | 1993-07-06 | E. R. Squibb & Sons, Inc. | Enteric coated pharmaceutical compositions |
DE69231281T2 (de) | 1991-12-17 | 2001-03-01 | Biovail Tech Ltd | Zusammensetzung und verfahren zur ulcusprävention und -behandlung |
SE9301830D0 (sv) | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
SE9302396D0 (sv) | 1993-07-09 | 1993-07-09 | Ab Astra | A novel compound form |
WO1995017080A1 (en) | 1993-12-14 | 1995-06-22 | Neo-Concepts, Inc. | Solid state power supply circuit for cold cathode lighting |
US5407687A (en) | 1994-02-22 | 1995-04-18 | Glaxo Inc. | Ranitidine solid dosage form |
US5945124A (en) | 1995-07-05 | 1999-08-31 | Byk Gulden Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
US6132768A (en) | 1995-07-05 | 2000-10-17 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors |
WO1997011750A1 (en) * | 1995-09-27 | 1997-04-03 | United Defense, L.P. | Integrated protective action system |
US6699885B2 (en) * | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
US20050054682A1 (en) | 1996-01-04 | 2005-03-10 | Phillips Jeffrey O. | Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same |
US6645988B2 (en) * | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
US5840737A (en) * | 1996-01-04 | 1998-11-24 | The Curators Of The University Of Missouri | Omeprazole solution and method for using same |
US6489346B1 (en) * | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
SE9600071D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients I |
SE9600072D0 (sv) | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients II |
US6949264B1 (en) | 1996-11-27 | 2005-09-27 | Wm. Wrigley Jr. Company | Nutraceuticals or nutritional supplements and method of making |
DE19709897A1 (de) | 1997-03-11 | 1998-09-17 | Hoechst Ag | Wismutsalze von Antibiotika der Moenomycin-Gruppe, Verfahren zu ihrer Herstellung, ihre Verwendung und solche Salze enthaltende Arzneimittel |
SE9700885D0 (sv) | 1997-03-12 | 1997-03-12 | Astra Ab | New pharmaceutical formulation |
SG109478A1 (en) * | 1997-07-22 | 2005-03-30 | Merck & Co Inc | Method for inhibiting bone resorption |
US6013680A (en) * | 1997-10-21 | 2000-01-11 | Amano Pharmaceutical Co., Ltd. | Digestive enzyme-containing medicament |
FR2772615B1 (fr) * | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
JP2000063280A (ja) * | 1998-06-11 | 2000-02-29 | Takeda Chem Ind Ltd | 抗ヘリコバクタ―・ピロリ活性胃腸薬 |
AU772726B2 (en) | 1998-08-12 | 2004-05-06 | Takeda Gmbh | Oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles |
ES2194515T3 (es) | 1998-10-06 | 2003-11-16 | Mars Uk Ltd | Estereotipia en animales. |
US6852739B1 (en) | 1999-02-26 | 2005-02-08 | Nitromed Inc. | Methods using proton pump inhibitors and nitric oxide donors |
DE19925710C2 (de) | 1999-06-07 | 2002-10-10 | Byk Gulden Lomberg Chem Fab | Neue Zubereitung und Darreichungsform enthaltend einen säurelabilen Protonenpumpenhemmer |
IL130602A0 (en) | 1999-06-22 | 2000-06-01 | Dexcel Ltd | Stable benzimidazole formulation |
US6316469B1 (en) | 2000-03-01 | 2001-11-13 | Duke University | Use of selective serotonin reuptake inhibitors for treatment of chest pain of non-cardiac origin and gastro-esophageal reflux disease |
US6483346B2 (en) * | 2000-11-15 | 2002-11-19 | Texas Instruments Incorporated | Failsafe interface circuit with extended drain services |
SE0101379D0 (sv) | 2001-04-18 | 2001-04-18 | Diabact Ab | Komposition som hämmar utsöndring av magsyra |
-
2002
- 2002-10-16 SE SE0203065A patent/SE0203065D0/xx unknown
-
2003
- 2003-10-15 WO PCT/SE2003/001598 patent/WO2004035090A1/en active Application Filing
- 2003-10-15 MX MXPA05004118A patent/MXPA05004118A/es unknown
- 2003-10-15 PL PL03376178A patent/PL376178A1/xx not_active Application Discontinuation
- 2003-10-15 US US10/531,598 patent/US7785626B2/en not_active Expired - Fee Related
- 2003-10-15 EP EP10075410A patent/EP2258341A3/en not_active Withdrawn
- 2003-10-15 CA CA2501201A patent/CA2501201C/en not_active Expired - Fee Related
- 2003-10-15 NZ NZ539262A patent/NZ539262A/en not_active IP Right Cessation
- 2003-10-15 KR KR1020057006582A patent/KR101139862B1/ko not_active IP Right Cessation
- 2003-10-15 RU RU2005114612/15A patent/RU2340358C2/ru not_active IP Right Cessation
- 2003-10-15 CN CN2003801063027A patent/CN1726048B/zh not_active Expired - Fee Related
- 2003-10-15 JP JP2004545135A patent/JP2006505566A/ja not_active Ceased
- 2003-10-15 AU AU2003267924A patent/AU2003267924C1/en not_active Ceased
- 2003-10-15 EP EP03748871A patent/EP1558288A1/en not_active Withdrawn
-
2005
- 2005-04-26 NO NO20052019A patent/NO20052019L/no not_active Application Discontinuation
-
2006
- 2006-10-10 US US11/544,750 patent/US7771747B2/en not_active Expired - Fee Related
-
2010
- 2010-02-19 US US12/660,056 patent/US20100151013A1/en not_active Abandoned
- 2010-12-24 JP JP2010288271A patent/JP2011057714A/ja active Pending
-
2012
- 2012-01-23 US US13/355,935 patent/US20120121664A1/en not_active Abandoned
- 2012-09-17 US US13/621,423 patent/US20130017263A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2004035090A1 (en) | 2004-04-29 |
JP2006505566A (ja) | 2006-02-16 |
EP2258341A3 (en) | 2012-08-29 |
RU2340358C2 (ru) | 2008-12-10 |
SE0203065D0 (sv) | 2002-10-16 |
CA2501201C (en) | 2013-01-08 |
US20130017263A1 (en) | 2013-01-17 |
US7785626B2 (en) | 2010-08-31 |
MXPA05004118A (es) | 2005-10-05 |
JP2011057714A (ja) | 2011-03-24 |
RU2005114612A (ru) | 2005-10-10 |
PL376178A1 (en) | 2005-12-27 |
AU2003267924A1 (en) | 2004-05-04 |
NO20052019D0 (no) | 2005-04-26 |
CN1726048A (zh) | 2006-01-25 |
US20120121664A1 (en) | 2012-05-17 |
US20100151013A1 (en) | 2010-06-17 |
KR101139862B1 (ko) | 2012-07-03 |
US7771747B2 (en) | 2010-08-10 |
AU2003267924B2 (en) | 2008-12-11 |
EP1558288A1 (en) | 2005-08-03 |
KR20050083770A (ko) | 2005-08-26 |
US20070031497A1 (en) | 2007-02-08 |
EP2258341A2 (en) | 2010-12-08 |
CA2501201A1 (en) | 2004-04-29 |
CN1726048B (zh) | 2012-05-30 |
AU2003267924C1 (en) | 2012-09-20 |
US20060115530A1 (en) | 2006-06-01 |
NZ539262A (en) | 2008-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20052019L (no) | Blanding for a inhibere sekresjon av magesyre | |
NO20060329L (no) | Paratyroid hormon (PTH) inneholdende farmasoytiske sammensetninger for oral anvendelse | |
RS115104A (en) | Pramipexole once-daily dosage form | |
DE60220403D1 (de) | Zusammensetzung zur unterdrückung von magensäure | |
LU92642I2 (fr) | Pomalidomide et ses sels, solvates, hydrates ou stéréoisomères pharmaceutiquement acceptables qui endérivent (Imnovid) | |
NO20074628L (no) | Formuleringer av octreotid med kontrollert frigjoring | |
CR9808A (es) | Procedimiento de tratamiento de la arterosclerosis, dispilidemias y afecciones relacionadas y composiciones farmaceuticas | |
CO5261535A1 (es) | Combinacion farmaceutica util para el tratamiento de movilidad gastrointestinal alterada, sensibilidad de secrecion, o desordenes abdominales | |
DK1414451T3 (da) | Opioidagonistformuleringer med frigivelig og sekvenstreret antagonist | |
NO20065638L (no) | Formuleringer med kontrollert frigivelse inneholdende vardenafil | |
IT1282352B1 (it) | Composizione farmaceutica, in particolare essiccata mediante congelamento, per somministrazione orale di ondansetron e metodo per | |
RU2010107843A (ru) | Бупропиона гидробромид и его терапевтические применения | |
EA200870368A1 (ru) | Антибиотические композиции с модифицированным высвобождением и способ их получения | |
CY1106763T1 (el) | Προληπτικα ή θεραπευτικα μεσα για φλεγμονωδεις νοσους του εντερου | |
EP3189854A1 (en) | Vaccine pharmaceutical composition for cell-mediated immunity containing bisphosphonates | |
CA2600773C (en) | Benzamidine derivatives for treatment and prevention of cancer therapy induced mucositis | |
EA200500985A1 (ru) | Твердая лекарственная форма для перорального применения | |
US6521266B1 (en) | Composition for growth hormone production and release, appetite suppression, and methods related thereto | |
IS6558A (is) | Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni | |
RU2019121690A (ru) | Дексмедетомидин или медетомидин для применения для лечения сепарационной тревожности у собак | |
CO5190664A1 (es) | Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2 | |
CO5580741A2 (es) | Composicion farmaceutica que comprende un agonista de receptor de 5ht1 | |
RU2008151727A (ru) | Комбинация аналогов соматостатина с антагонистом рецептора дофамина или рецептора гормона роста | |
BR1100108A (pt) | Agonista receptor como 5-ht1 para administração retal | |
RS20050796A (en) | Pharmaceutical compositions comprising a proton pump inhibitor and a prokinetic agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |